Τετάρτη 9 Οκτωβρίου 2019

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin: Condition:   Solid Tumors

Interventions:   Drug: Savolitinib;   Drug: Rifampicin

Sponsor:   AstraZeneca

Not yet recruiting



Hide glossaryGlossary

Study record managers: refer to the Data Element Definitions if submitting registration or results information.



Search for terms



x

Accepts healthy volunteers

Active comparator arm

Adverse event

Age or age group

All-cause mortality

Allocation

Arm

Arm type

Baseline characteristics

Canceled submission

Certain agreements

Certification

Certification/extension first posted

Certification/extension first submitted

Certification/extension first submitted that met QC criteria

City and distance

Clinical study

Clinical trial

ClinicalTrials.gov identifier (NCT number)

Collaborator

Condition/disease

Contact

Country

Cross-over assignment

Data Monitoring Committee (DMC)

Early Phase 1 (formerly listed as Phase 0)

Eligibility criteria

Enrollment

Exclusion criteria

Expanded access

Expanded access status

Expanded access type

Experimental arm

Extension request

Factorial assignment

First posted

First submitted

First submitted that met QC criteria

Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801)

Funder type

Gender-based eligibility

Group/cohort

Human subjects protection review board

Inclusion criteria

Informed consent

Informed consent form (ICF)

Intervention model

Intervention/treatment

Interventional study (clinical trial)

Investigator

Last update posted

Last update submitted

Last update submitted that met QC criteria

Last verified

Listed location countries

Location terms

Masking

NCT number

No intervention arm

Observational study

Observational study model

Other adverse event

Other study IDs

Other terms

Outcome measure

Parallel assignment

Participant flow

Patient registry

Phase

Phase 1

Phase 2

Phase 3

Phase 4

Phase Not Applicable

Placebo

Placebo comparator arm

Primary completion date

Primary outcome measure

Primary purpose

Principal investigator (PI)

Protocol

Quality control (QC) review

Randomized allocation

Recruitment status

Registration

Removed location countries

Reporting group

Responsible party

Results database

Results delayed

Results first posted

Results first submitted

Results first submitted that met QC criteria

Results returned after quality control review

Results submitted to ClinicalTrials.gov

Secondary outcome measure

Serious adverse event

Sex

Sham comparator arm

Single group assignment

Sort studies by

Sponsor

State

Statistical analysis plan (SAP)

Status

Study completion date

Study design

Study documents

Study IDs

Study record

Study registry

Study results

Study start date

Study type

Submitted date

Title

Title acronym

U.S. Agency for Healthcare Research and Quality (AHRQ)

U.S. Food and Drug Administration (FDA)

Unknown

Skip to Main Content

ClinicalTrials.gov

Find StudiesFind Studies Menu

About StudiesAbout Studies Menu

Submit StudiesSubmit Studies Menu

ResourcesResources Menu

About SiteAbout Site Menu

HomeSearch ResultsStudy Record Detail Save this study

A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.



ClinicalTrials.gov Identifier: NCT04118842

Recruitment Status  : Not yet recruiting

First Posted  : October 8, 2019

Last Update Posted  : October 8, 2019

See Contacts and Locations

Sponsor:

AstraZeneca

Information provided by (Responsible Party):

AstraZeneca



Study DetailsTabular ViewNo Results PostedDisclaimerHow to Read a Study Record

Study Description

Go to  sections

Brief Summary:

This is a phase I, open-label, 3 treatment period, fixed-sequence study in healthy non-Japanese vasectomized male subjects, aged 18 to 55 years or healthy non-Japanese male subjects over 45 to 55 years old, performed at a single study centre. Treatment Period 1 will establish the single dose pharmacokinetic (PK) profile of savolitinib. Dosing of daily rifampicin during Treatment Period 2 will result in maximal induction of the CYP450 enzymes including CYP3A4. Treatment Period 3 will then establish the single dose PK profile of savolitinib under maximum CYP450 induction conditions. Comparison of the PK profile of savolitinib between Treatment Period 1 and Treatment Period 3 will quantify the effect of CYP450 enzyme induction.



Condition or disease Intervention/treatment Phase 

Solid Tumors

Drug: Savolitinib

Drug: Rifampicin

Phase 1



Detailed Description:

The treatment starts with a single dose of savolitinib (Treatment Period 1), followed by a washout period at least of 14 days after savolitinib dosing and before the start of Treatment Period 2, followed by rifampicin administration for 5 days (Treatment Period 2), and lastly, a combination of savolitinib + rifampicin (Treatment Period 3). Overall, all subjects will receive 2 single doses of 600 mg savolitinib and 7 daily doses of 600 mg rifampicin. Subjects will be resident in the study centre when receiving study drug administrations (savolitinib [Treatment Period 1], rifampicin [Treatment Period 2] and savolitinib+rifampicin [Treatment Period 3]). Subjects are required to fast overnight before each dosing day. Rifampicin will be administered 1 hour before breakfast with 240 mL water. The subjects will need to complete high-fat, high calorie breakfast before administration of savolitinib in Treatment Period 1, Day 1 (Study Day 1) and Treatment Period 3 Day 1 (Study Day 20).



Study Design

Go to  sections

Study Type  : Interventional  (Clinical Trial)

Estimated Enrollment  : 16 participants

Allocation: Non-Randomized

Intervention Model: Sequential Assignment

Masking: None (Open Label)

Primary Purpose: Basic Science

Official Title: An Open-label, 3-period Fixed-sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

Estimated Study Start Date  : October 7, 2019

Estimated Primary Completion Date  : November 28, 2019

Estimated Study Completion Date  : November 28, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Rifampin

U.S. FDA Resources



Arms and Interventions

Go to  sections

Arm Intervention/treatment 

Experimental: Savolitinib and/or Rifampicin

Treatment Period 1 consists of 16 days starting with admission on Study Day -1, followed by a single dose administration of savolitinib on Day 1, followed by a washout period of at least 14 days. Subjects will be discharged from the Study Centre on Study Day 3, after the last PK sample is collected Treatment Period 2 consists of 6 days, starting with admission on Study Day 14, followed by QD dose administrations of rifampicin for 5 consecutive days (Study Day 15 to Study Day 19) Treatment Period 3 consists of 4 days, starting immediately after Treatment Period 2, comprising of a single dose administration of savolitinib on Study Day 20 and QD dose administration of rifampicin on Study Day 20 and Study Day 21. Subjects will be discharged from the Study Centre on Study Day 22, after the last PK sample is collected

Drug: Savolitinib

Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.



Drug: Rifampicin

Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.

Other Name: Rifampin







Outcome Measures

Go to  sections

Primary Outcome Measures  :

Savolitinib: Maximum plasma concentration (Cmax) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To assess the effect of rifampicin on the PK of savolitinib



Area under the curve (AUC) ratios of geometric means of test treatment (savolitnib+rifampicin) relative to reference treatment (savolitinib alone) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To assess the effect of rifampicin on the PK of savolitinib





Secondary Outcome Measures  :

Number of subjects with adverse events [ Time Frame: Only SAEs at Screening; AEs from Study Days 1 to 34 ]

To assess the adverse events as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in systolic blood pressure (BP) [ Time Frame: At Screening, and from Study Days 1 to 14 and Study Days 20 to 22 ]

To assess vital sign as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in diastolic BP [ Time Frame: At Screening, and from Study Days 1 to 14 and Days 20 to 22 ]

To assess vital sign as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in pulse rate [ Time Frame: At Screening, and from Study Days 1 to 14 and Study Days 20 to 22 ]

To assess vital sign as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings inelectrocardiograms (ECGs) (12-lead ECGs) [ Time Frame: At Screening, and from Study Days 1 to 34 ]

To assess any clinically important abnormalities in cardiovascular function based on the 12-lead ECGs as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in physical examinations [ Time Frame: At Screening, from Study Days -1 to 22 (brief) and Study Day 34 ]

To assess any clinically important abnormal findings in physical conditions as a variable of safety and tolerability of savolitinib in combination with rifampicin. The complete physical examinations will include an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head and neck, lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations will include an assessment of the general appearance, skin, abdomen, cardiovascular system and respiratory.



Number of subjects with abnormal findings in white blood cell (WBC) count [ Time Frame: From Screening to Study Day 34 ]

To assess the WBC count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in red blood cell (RBC) count [ Time Frame: From Screening to Study Day 34 ]

To assess the RBC count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in hemoglobin (Hb) [ Time Frame: From Screening to Study Day 34 ]

To assess Hb as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in hematocrit (HCT) [ Time Frame: From Screening to Study Day 34 ]

To assess HCT as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in mean corpuscular volume (MCV) [ Time Frame: From Screening to Study Day 34 ]

To assess MCV as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in mean corpuscular hemoglobin (MCH) [ Time Frame: From Screening to Study Day 34 ]

To assess MCH as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in mean corpuscular hemoglobin concentration (MCHC) [ Time Frame: From Screening to Study Day 34 ]

To assess MCHC as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in neutrophils absolute count [ Time Frame: From Screening to Study Day 34 ]

To assess the neutrophils absolute count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in lymphocytes absolute count [ Time Frame: From Screening to Study Day 34 ]

To assess the lymphocytes absolute count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in monocytes absolute count [ Time Frame: From Screening to Study Day 34 ]

To assess the monocytes absolute count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in eosinophils absolute count [ Time Frame: From Screening to Study Day 34 ]

To assess the eosinophils absolute count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in basophils absolute count [ Time Frame: From Screening to Study Day 34 ]

To assess the basophils absolute count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in platelets [ Time Frame: From Screening to Study Day 34 ]

To assess platelets as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in reticulocytes absolute count [ Time Frame: From Screening to Study Day 34 ]

To assess the reticulocytes absolute count as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in sodium [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (sodium) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in potassium [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (potassium) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in urea [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (urea) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in creatinine [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (creatinine) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in albumin [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (albumin) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in calcium [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (calcium) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in phosphate [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (phosphate) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in glucose (fasting) [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (glucose [fasting]) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in c-reactive protein (CRP) [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (CRP) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of participants with abnormal findings in liver enzymes [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value of liver enzymes as a variable of safety and tolerability of savolitinib in combination with rifampicin. The laboratory variables to be measured are: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transpeptidase (GGT)



Number of subjects with abnormal findings in total bilirubin [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (total bilirubin) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in unconjugated bilirubin [ Time Frame: From Screening to Study Day 34 ]

To assess the clinical chemistry value (unconjugated bilirubin) as a variable of safety and tolerability of savolitinib in combination with rifampicin



Number of subjects with abnormal findings in urinalysis [ Time Frame: From Screening to Study Day 34 ]

To assess the urinalysis as a variable of safety and tolerability of savolitinib in combination with rifampicin. The laboratory variables to be measured are protein, glucose, and blood.



Number of subjects with abnormal findings in urinalysis (microscopy) [ Time Frame: From Screening to Study Day 34 ]

To assess the urinalysis microscopy (if positive for protein or blood) as a variable of safety and tolerability of savolitinib in combination with rifampicin. The laboratory variables to be measures are RBC, WBC, casts (cellular, granular, hyaline).



Savolitinib: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To assess the effect of rifampicin on the PK of metabolites N-desmethyl savolitinib or 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1H-pyrazol-4-yl)triazolo[4,5-b]pyrazine (M2) and 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1 methylpyrazol-4-yl)triazolo[4,5-b]pyrazin-5-ol (M3)



M2 and M3: Cmax ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



M2 and M3: AUC ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



M2 and M3: AUC(0-t) ratios of geometric means of test treatment (savolitinib+rifampicin), relative to reference treatment (savolitinib alone) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of Cmax [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: summary PK profiles and descriptive statistics of AUC(0 t) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: Ratio of metabolite AUC to parent AUC (MRCAUC) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: Ratio of metabolite AUC(0-t) to parent AUC(0-t) (MRCAUC[0-t]) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: metabolite-to-parent ratios for Time to reach maximum observed plasma concentration (tmax) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: metabolite-to-parent ratios for Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2,λz) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: metabolite-to-parent ratios for terminal elimination rate constant (λz) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only)CL/F [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, when it is administered alone and in combination with rifampicin



Savolitinib, M2 and M3: Ratio of metabolite Cmax to parent Cmax (MRCmax) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib, M2 and M3 when savolitinib is administered alone and in combination with rifampicin



Savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) (Vz/F) [ Time Frame: Treatment Period 1 (Study Days 1 to 14) and Treatment Period 3 (Study Days 20 to 22) at pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18, 24, 36 and 48 hours after study drug administration ]

To describe the PK parameters and the PK profiles for savolitinib it is administered alone and in combination with rifampicin





Eligibility Criteria

Go to  sections

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.





Ages Eligible for Study:  18 Years to 55 Years   (Adult)

Sexes Eligible for Study:  Male

Gender Based Eligibility:  Yes

Gender Eligibility Description:  Male

Accepts Healthy Volunteers:  Yes

Criteria

Inclusion Criteria:



For inclusion in the study subjects should fulfil the following criteria:



Provision of signed and dated, written informed consent prior to any study specific procedures.

Healthy male subjects with suitable veins for cannulation or repeated venipuncture: non Japanese vasectomized male subjects aged 18 to 55 years (inclusive) or male subjects over 45 (and up to 55) years old not intending to father children for 6 months after last dose of savolitinib.

Have a body mass index between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

Alanine aminotransferase, AST and total bilirubin less than or equal to the upper limit of normal for the institution.

Have a calculated creatinine clearance greater than 80 mL/min using the Cockcroft-Gault formula at screening.

Provision of signed, written and dated informed consent for optional genetic/biomarker research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this clinical study protocol.

Exclusion Criteria:



Subjects will not enter the study if any of the following exclusion criteria are fulfilled:



Healthy subjects of Japanese ethnicity and any healthy subject that has 1 parent or grandparent (maternal or paternal) of Japanese ethnicity.

History of any clinically significant disease or disorder which, in the opinion of the Principal Investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.

History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).

Planned in-patient surgery, dental procedure or hospitalization during the study.

Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the PI.

Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.

Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

(1) Systolic BP < 90 mmHg or ≥ 140 mmHg (2) Diastolic BP < 50 mmHg or ≥ 90 mmHg (3) Heart rate < 45 or > 85 beats per minute. 9 Any clinically important abnormalities in rhythm, conduction or morphology of the 12 lead resting ECG that may interfere with the interpretation of QTc interval changes. These include healthy subjects with any of the following:



Abnormal ST-T-wave morphology, particularly in the protocol defined primary lead (V2) or left ventricular hypertrophy.

PR interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation).

PR interval prolongation (> 200 ms). Intermittent second (Type 1 second degree block [Wenckebach Phenomenon] while asleep is not exclusive]) or third degree atrioventricular (AV) block, or AV dissociation.

Persistent or intermittent complete bundle branch block, incomplete bundle branch block, or intraventricular conduction delay with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of e.g., ventricular hypertrophy or pre-excitation.

Mean resting correct QT interval (QTcF) > 450 ms for men on screening obtained from 3 ECGs or history or factors that may increase the risk of QTcF prolongation such as chronic hypokalaemia not correctable with supplements, congenital or familial long QT syndrome, or family history of unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes (TdP).

10 Known or suspected history of drug abuse, as judged by the PI. 11 Current smokers or those who have smoked or used nicotine products within the previous 30 days.



12 History of alcohol abuse or excessive intake of alcohol as judged by the PI. 13 Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate,) as judged by the PI.



14 Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of the IMP.



15 Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first admission on Day -1.



16 Use of any prescribed or non-prescribed medication including antacids, analgesics (other than use of ibuprofen up to 72 hours before dosing day), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks before the first administration of the IMP or longer (5 times the half-life) if the medication has a long half-life. No medications known to prolong the QT/QTc interval and cause TdP are allowed.



17 Positive screen for drugs of abuse, cotinine (nicotine) and/or alcohol at screening and at admission to the Study Centre (Day -1 [Period 1] and Day 14 [Period 2]) to the Study Centre.



18 History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI.



19 History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to savolitinib or rifampicin.



20 Plasma donation within 1 month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.



21 Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.



Note: subjects consented and screened, but not enrolled in this study or a previous phase I study, are not excluded.



22 Involvement of any AstraZeneca, Parexel or study site employee or their close relatives 23 Subjects who have previously received savolitinib. 24 Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.



25 Subjects who are vegans, vegetarians or have medical dietary restrictions and who are lactose intolerant.



26 Subjects who cannot communicate reliably with the PI. 27 Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.



28 Subjects who wear soft contact lenses, unless the subject is prepared to refrain from wearing soft lenses throughout Period 2 until after the last PK sample collection in Period 3.



Contacts and Locations

Go to  sections

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.



Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04118842





Contacts

Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com



Locations

United States, Maryland

Research Site Not yet recruiting

Baltimore, Maryland, United States, 21225

Sponsors and Collaborators

AstraZeneca

More Information

Go to  sections



Responsible Party: AstraZeneca

ClinicalTrials.gov Identifier: NCT04118842     History of Changes

Other Study ID Numbers: D5084C00003

First Posted: October 8, 2019    Key Record Dates

Last Update Posted: October 8, 2019

Last Verified: October 2019

Studies a U.S. FDA-regulated Drug Product: Yes

Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AstraZeneca:

Solid tumors

Small-molecule kinase inhibitor

Additional relevant MeSH terms:

Rifampin

Antibiotics, Antitubercular

Antitubercular Agents

Anti-Bacterial Agents

Anti-Infective Agents

Leprostatic Agents

Nucleic Acid Synthesis Inhibitors

Enzyme Inhibitors

Molecular Mechanisms of Pharmacological Action

Cytochrome P-450 CYP2B6 Inducers

Cytochrome P-450 Enzyme Inducers

Cytochrome P-450 CYP2C8 Inducers

Cytochrome P-450 CYP2C19 Inducers

Cytochrome P-450 CYP2C9 Inducers

Cytochrome P-450 CYP3A Inducers





TO TOP

For Patients and Families For Researchers For Study Record Managers

HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CUSTOMER SUPPORT

Copyright Privacy Accessibility Viewers and Players Freedom of Information Act USA.gov



U.S. National Library of Medicine U.S. National Institutes of Health U.S. Department of Health and Human Services


Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου